PDS0104 is a novel investigational Tyrosinase-related Protein 2 (TRP2)-targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. PDS0104 is given by a simple subcutaneous injection alone or in combination with other immunotherapies and cancer treatments. Preclinical data suggests PDS0104 generates clinically effective immune responses, and demonstrates significant disease control by shrinking tumors, delaying disease progression and/or prolonging survival.
About 96,000 new melanomas are diagnosed each year, more than 7,000 of which are fatal. The rates of melanoma have been rising rapidly over the past few decades. Melanoma can be targeted by the Currently melanoma is treated with surgery, chemotherapy, radiation and immunotherapies either alone or in combination. There remains a high unmet need for more effective, safer, better tolerated and melanoma treatment options.
PDS0104 is currently in late-stage pre-clinical development.